Key findings from published and presented studies include: In a phase 2 obesity trial, higherdose retatrutide produced average weight loss of around 22.824.2% over 48 weeks in people with obesity. In participants with type 2 diabetes, retatrutide achieved substantial weight loss and marked improvements in blood sugar and cardiometabolic markers, though average percentage weight loss was somewhat lower than in nondiabetic obesity cohorts. Early studies also reported significant reductions in liver fat and visceral adipose tissue, with a high proportion of participants with fatty liver disease showing resolution of hepatic steatosis at higher doses. These results have led several reviews to describe retatrutide as a potential game changer in obesity pharmacotherapy, representing the first GLP1/GIP/glucagon triple agonist with robust human data. Popular coverage has highlighted phase 3 data suggesting average weight losses approaching 29% of body weight in some cohorts (roughly 71 pounds), which is about double typical results with semaglutide over comparable periods

That matters for semaglutide because product selection between Ozempic and Wegovy is often a specialist-led decision when BMI is borderline (27 to 30 with comorbidity)
Verify with a dosing chart
Treatment of duodenal ulcer with antacid and sulpiride
In the clinic, we prescribe it orally or inhaled using a nebulizer to thin mucus in chronic respiratory diseases
Note: The cost of the medication is separate from cost of the clinician visit